evipedia.ai
← Back

Topical NMN for Skin Rejuvenation

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: Topical Nicotinamide Mononucleotide, Topical β-Nicotinamide Mononucleotide, Nicotinamide Mononucleotide, β-Nicotinamide Mononucleotide, NMN, β-NMN, NMN Serum, NMN Cream

Motivation

Topical nicotinamide mononucleotide (NMN) is a form of vitamin B3 applied to the skin in creams, serums and ampoules. Inside cells it is a direct building block of a molecule that powers energy production and DNA repair, and the level of that molecule falls in human skin with age. This has made NMN a popular ingredient in longevity-oriented skincare, marketed to smooth wrinkles, restore firmness and even out skin tone.

NMN first drew wide attention as an oral supplement after mouse studies tested whether it could slow several features of aging. Skincare brands then began adding it to their products, reasoning that applying it directly could raise levels where skin ages. Human testing of the topical form so far consists of a few small, company-funded cosmetic studies, alongside laboratory and animal work.

This review examines what is known about applying NMN to the skin: whether it gets in, what changes have been measured in people, what laboratory and animal studies suggest, how safe it is, and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

Expert commentary and research giving a high-level overview of NMN, the NAD+ (nicotinamide adenine dinucleotide, a coenzyme cells need for energy production and DNA repair) pathway it feeds, and its application to skin.

Chris Kresser’s main NMN content is an interview with David Sinclair that overlaps the listed Huberman Lab episode, and Life Extension’s NMN material is promotional coverage of its own oral products; with the list capped at five, neither is included. No priority expert addresses topical NMN or skin in depth.

Grokipedia

Nicotinamide mononucleotide

Covers NMN biochemistry, human trials and the US regulatory dispute over its supplement status; it does not address topical or skin use, so it provides background rather than skin-specific evidence.

Examine

Nicotinamide Mononucleotide

Summarizes oral human trials at 250–1,200 mg daily and states that benefits seen in animals remain unproven in humans; it offers no topical or skin-specific analysis.

ConsumerLab

NAD Booster Supplements Review (NAD+/NADH, Nicotinamide Riboside, and NMN)

Tests oral NAD booster supplements, including NMN, for label accuracy and heavy-metal contamination and weighs their clinical evidence and safety concerns; topical NMN products are not tested.

Systematic Reviews

Systematic reviews of NMN in humans; none examines topical application or skin outcomes, so the claimed skin benefit is unrepresented and both listed papers concern oral use and its principal risk, systemic safety.

Mechanism of Action

Inside cells, NMNAT enzymes (which attach an adenine group) convert NMN into NAD+. Human skin NAD+ falls with age as DNA damage accumulates (Massudi et al., 2012). Restoring it may support sirtuins (NAD+-dependent stress-resistance enzymes) and PARPs (poly(ADP-ribose) polymerases, DNA-repair enzymes); in cell studies this yields more collagen, fewer senescent (permanently arrested) cells and lower melanin output from aged pigment cells.

Two uptake models compete. One holds that NMN enters cells through dedicated transporters (Slc12a8, a solute-carrier gene, in mouse gut; SLC12A6 proposed in pigment cells by Brito et al., 2022). The other shows NMN is converted outside cells to nicotinamide riboside (NR), then re-phosphorylated by NRK1 (nicotinamide riboside kinase 1, which adds a phosphate) (Ratajczak et al., 2016). Whether NMN raises NAD+ in skin cells is contested: it did in collagen-producing fibroblasts in cosmetics maker LG Household & Health Care’s study (Kang et al., 2025), but not in keratinocytes (surface skin cells), where nicotinic acid worked better in another cosmetics maker’s study (Oyama et al., 2024).

NMN is a small, charged, water-soluble substrate, not a receptor-selective drug, so it crosses the skin’s oily barrier poorly; in an artificial membrane it reached only the upper-dermis equivalent (Betsuno et al., 2025, with BYU-Analytica co-authors). CYP (cytochrome P450, drug-metabolizing liver enzymes) pathways are uninvolved; excess is broken down to nicotinamide and excreted as methylated metabolites (Irie et al., 2020). Oral NMN leaves mouse blood within minutes (Mills et al., 2016, co-authored by NMN maker Oriental Yeast); skin residence time is unmeasured.

Historical Context & Evolution

NMN was characterized in the mid-twentieth century as an intermediate in NAD+ synthesis by biochemists mapping how cells build energy coenzymes; it had no intended use as a product. Interest shifted in the 2010s when Shin-ichiro Imai’s laboratory showed that oral NMN raised tissue NAD+ in mice and blunted age-related weight gain, insulin resistance and decline in eye function (Mills et al., 2016). Public advocacy by Harvard researcher David Sinclair helped turn it into a best-selling longevity supplement, and the first human safety study followed in Japan, finding single oral doses up to 500 mg well tolerated (Irie et al., 2020).

Cosmetic use grew from evidence that human skin NAD+ declines with age (Massudi et al., 2012). Swiss brand Seneque registered a cream trial against a reference product in 2020 (NCT04685096), but no results have been posted. The first published human data on topical NMN arrived in 2026 from a Korean study funded by the ampoule maker DEFY NUMBER and co-authored by employees of the device maker Hironic (Hong et al., 2026).

Opinion has moved in both directions. Oral human trials have shown reliable rises in blood NAD+ but inconsistent functional benefits (Gallagher & Emmanuel, 2026), tempering early enthusiasm, while delivery-technology and skin-cell studies have renewed interest in applying NMN directly. The US Food and Drug Administration excluded NMN from supplements in 2022, then reversed that position in 2025.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human trial with a clinical skin endpoint has tested topical NMN against a vehicle control, let alone replicated such a result.

Medium 🟩 🟩

No benefit reaches Medium: the only published human data on topical NMN alone come from one uncontrolled, open-label within-face comparison, not from a controlled trial or consistent observational data.

Low 🟩

Fine Lines, Wrinkles and Firmness

Twice-daily 10% nano-NMN ampoule modestly reduced wrinkle depth and pore volume and improved elasticity over four weeks in 21 Korean women (Hong et al., 2026). No vehicle control; the ampoule also contained niacinamide and adenosine; the maker funded it. Fibroblast studies show more collagen (Kang et al., 2025).

Magnitude: Within-side changes after 4 weeks of topical-only use: periorbital (around-the-eye) wrinkle depth −3.83%, nasolabial (nose-to-mouth) fold depth −4.29%, pore volume −6.57%, gross elasticity (R2, a suction-device recovery score) +1.36% (Hong et al., 2026).

Uneven Pigmentation

NMN lowered melanin production in aged, but not young, human pigment cells and in reconstructed human skin by damping cAMP/Wnt signaling (growth-signal pathways that switch on pigment genes) (Brito et al., 2022). In people, the only data come from the same uncontrolled ampoule study, whose niacinamide content independently fades pigment.

Magnitude: Within-side changes after 4 weeks of topical-only use: melanin intensity −7.75% and hyperpigmented area −13.34% (Hong et al., 2026).

Skin Hydration

Oral NMN restored hyaluronic-acid-producing enzymes and normalized water loss in ultraviolet-B-exposed mice (Kim et al., 2025), a study co-authored by LG Household & Health Care scientists. In people, topical-only use raised tissue water in one uncontrolled, multi-ingredient study.

Magnitude: Within-side increases in tissue water content after 4 weeks: +8.21% at 0.5 mm, +3.81% at 1.5 mm and +1.99% at 2.5 mm depth (Hong et al., 2026).

Speculative 🟨

Protection Against Ultraviolet Photodamage

NMN injected into the abdominal cavity or given orally preserved collagen in ultraviolet-B-exposed mice (Zhou et al., 2021, co-authored by supplier Effepharm; Kim et al., 2025). No topical or human data exist; animal basis only.

Relief of Inflammatory Skin Disease ⭕️ Not Central to Skin Rejuvenation

Topical NMN eased dermatitis-like lesions in mice (Gao et al., 2022) and curbed inflammation in NAD+-deficient mouse skin (Seki et al., 2026). This bears on eczema and psoriasis, not rejuvenation; animal data only.

Wound Healing ⭕️ Not Central to Skin Rejuvenation

NMN sped wound closure in cultured human fibroblasts (Kang et al., 2025), and NMN-coated nanoparticle dressings aided diabetic mouse wounds (Tang et al., 2026). This bears on repair, not rejuvenation; laboratory and animal data only.

Hair Growth ⭕️ Not Central to Skin Rejuvenation

NMN reversed male-hormone-induced hair follicle shrinkage in mice and protected cultured human hair-growth control cells (Xu et al., 2024). This bears on scalp hair, not facial skin; animal and cell data only.

Benefit-Modifying Factors

  • Genetic polymorphisms: No study links variants in NAMPT (the rate-limiting NAD+ recycling enzyme), NNMT (which tags nicotinamide for excretion) or CD38 (a major NAD+-consuming enzyme) to topical NMN response; any genetic influence remains unknown.
  • Baseline skin NAD+ and photodamage: Skin NAD+ falls with age and DNA damage (Massudi et al., 2012), so older, sun-damaged skin has more theoretical headroom; NMN reduced pigment only in aged, not young, pigment cells (Brito et al., 2022).
  • Sex: Human topical data come only from women (Hong et al., 2026; NCT04685096); skin NAD+ decline correlated more strongly with age in men (Massudi et al., 2012), but sex-specific responses are untested.
  • Pre-existing conditions: A compromised barrier (eczema, recent procedures) raises penetration but also irritation; thick or oily skin may absorb less of this water-soluble molecule. Mouse data suggest NAD+-depleted, inflamed skin responds most (Seki et al., 2026).
  • Age: Published human data cover women aged 47–73 (mean 62); no data exist for skin beyond the mid-seventies, where thinner epidermis may raise penetration while lower repair capacity may limit response.
  • Delivery vehicle: Elastic cationic liposomes (flexible, positively charged fat-based carriers) raised NMN skin penetration by 22.7% over free NMN (Ye et al., 2026); device-assisted delivery produced larger changes than topical application alone (Hong et al., 2026).

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no controlled human trial has documented an adverse event attributable to topical NMN, and topical safety data are limited to small cosmetic studies.

Medium 🟥 🟥

No risk reaches Medium: no single controlled trial or consistent observational dataset has recorded harm from topical NMN.

Low 🟥

Local Irritation and Stinging

No irritation, burning or scaling was reported with twice-daily 10% nano-NMN over four weeks in 21 women (Hong et al., 2026). NMN breaks down to niacinamide, which caused no stinging up to 10% (Cosmetic Ingredient Review, 2005, industry-funded); vehicles, acids and penetration enhancers remain plausible irritants.

Magnitude: 0 of 21 participants reported redness, swelling, scaling, itching, stinging or burning after 4 weeks of twice-daily use (Hong et al., 2026).

Complications of Device-Assisted Delivery

Microneedling or microjet (high-pressure spray) delivery pushes serums past the skin barrier; cosmetic serums driven into the dermis by microneedling caused allergic facial granulomas (chronic inflammatory nodules) and systemic hypersensitivity in three patients (Soltani-Arabshahi et al., 2014). No NMN-specific case exists; the risk derives from the delivery method.

Magnitude: Not quantified in available studies. Only case reports exist, and none involved an NMN product.

Systemic Effects of Absorbed NMN

Any NMN crossing the skin enters the same pathway as oral NMN. In a meta-analysis of randomized trials, oral NMN at 250–2,000 mg/day for up to 24 weeks did not increase adverse events or liver enzymes (Yang et al., 2026); topical doses are far smaller.

Magnitude: Total adverse events risk difference −0.8 percentage points versus control (95% confidence interval, the range likely to hold the true value, −6.1 to +4.5) across 10 oral trials with 383 participants (Yang et al., 2026); systemic exposure after topical use has not been measured.

Speculative 🟨

Amplified Senescence-Associated Inflammation

In cell studies, raising NAD+ via NAMPT amplified inflammatory secretions from senescent (permanently arrested) cells (Nacarelli et al., 2019). Whether topical NMN does this in aged skin is unknown; mechanistic basis only.

Support for Pre-Malignant Skin Cells

NAD+ fuels rapidly dividing cells, including tumor cells, raising a theoretical concern over sun-damaged skin. Oral NMN neither promoted nor prevented ultraviolet-induced skin tumors in mice (Pihl et al., 2025); topical data are absent.

Unstudied Use in Pregnancy and Breastfeeding

No study has assessed topical NMN during pregnancy or lactation; trials excluded pregnant or nursing women (NCT04685096). The concern rests on absent data, not observed harm.

Risk-Modifying Factors

  • Genetic polymorphisms: No pharmacogenetic data exist. NMN bypasses CYP enzymes; NNMT variants, which alter nicotinamide clearance, are theoretically relevant only to systemic exposure, which is minimal with topical use.
  • Baseline biomarkers: No blood marker predicts topical risk. Baseline transepidermal water loss (TEWL, water evaporating through the skin barrier) and known irritant sensitivity matter more than systemic NAD+ levels.
  • Sex: No sex differences in adverse events have been reported; topical safety data come almost entirely from women.
  • Pre-existing conditions: Rosacea (a chronic facial redness condition), eczema or prior contact allergy raise irritation risk; broken skin raises absorption; a history of skin cancer heightens the theoretical pre-malignant cell concern.
  • Age: Older, thinner skin irritates and absorbs more readily; no topical safety data exist beyond age 73.
  • Delivery method: Microneedling, electroporation (brief electrical pulses that open skin pathways) or microjet delivery adds infection and allergic granuloma risk, especially with cosmetic serums not made for use in the dermis (Soltani-Arabshahi et al., 2014).

Key Interactions & Contraindications

  • Prescription topical retinoids (vitamin A-derived creams such as tretinoin, tazarotene, adapalene): Caution. No pharmacologic interaction, but layering NMN on retinoid-irritated skin may increase stinging and redness. Mitigation: alternating nights until retinoid tolerance is established limits cumulative irritation.
  • Prescription depigmenting agents (hydroquinone, triple-combination creams): Monitor. Possible additive lightening, with a risk of uneven pallor around treated spots. Mitigation: monthly standardized photographs of pigmented areas.
  • PARP inhibitors (cancer drugs that block DNA repair, such as olaparib, niraparib): Caution, theoretical. Raising NAD+ could in principle oppose drugs exploiting NAD+-dependent repair; systemic exposure from topical use is likely negligible. Mitigation: the treating oncologist being informed of use allows case-by-case review.
  • Over-the-counter acids and vitamin C serums (glycolic acid, salicylic acid, L-ascorbic acid): Caution. Low pH (higher acidity) accelerates NMN breakdown and may convert its niacinamide product to nicotinic acid, causing transient flushing. Mitigation: a 20–30 minute gap, or different times of day, limits contact.
  • Over-the-counter benzoyl peroxide (acne gels and washes): Monitor. A strong oxidant that may degrade NMN on the skin, reducing effect. Mitigation: application at opposite times of day avoids direct contact.
  • Oral NAD+ precursor supplements (NMN, nicotinamide riboside, nicotinamide, niacin): Monitor. Additive vitamin B3 load; consequence is higher total precursor exposure and, with niacin, flushing. Mitigation: tallying total daily B3 intake keeps exposure in view; the topical contribution is small.
  • Supplements with overlapping targets (resveratrol, pyrroloquinoline quinone, coenzyme Q10, collagen peptides): Monitor. Additive sirtuin, mitochondrial or collagen effects are plausible; no harmful interaction is known. Mitigation: introducing one product at a time allows benefit or irritation to be attributed.
  • Microneedling, electroporation, microjet and fractional laser procedures: Caution. They increase NMN penetration and the risk of infection or allergic granulomas from cosmetic products. Mitigation: only sterile, procedure-grade formulations applied by trained practitioners.

Populations who should avoid Topical NMN:

  • Known allergy to NMN or any listed ingredient (e.g., a positive patch test to the formulation’s preservative or fragrance)
  • Pregnancy (any trimester) or breastfeeding, owing to absent safety data
  • Active skin cancer (basal cell carcinoma, squamous cell carcinoma or melanoma) or an undiagnosed changing lesion within the application area, until cleared by a dermatologist
  • Broken or acutely inflamed skin: open wounds, an active eczema flare, or within 7–14 days after ablative laser, a medium-depth or deep chemical peel, or microneedling

Risk Mitigation Strategies

  • Patch test before facial use: Application to the inner forearm or behind the ear twice daily for 3–5 days precedes facial use; redness, itching or swelling signals stopping. Mitigates local irritation and allergic contact reactions.
  • Low starting concentration and frequency: Protocols begin with a 2–5% product once daily for 1–2 weeks before moving to twice-daily or 10% products. Reduces stinging and irritation.
  • Separation from acids and oxidants: NMN is applied 20–30 minutes apart from, or at the opposite time of day to, acids, vitamin C or benzoyl peroxide. Prevents NMN degradation and niacinamide-related flushing.
  • Procedure-grade products only with devices: Only sterile formulations labelled for intradermal or procedural use are applied during microneedling or microjet delivery, performed by trained clinicians. Prevents allergic granulomas and skin infection.
  • Skin checks for changing lesions: A full-skin examination at baseline and yearly (every 6 months with prior skin cancer); product is not applied over new or changing spots. Addresses the theoretical pre-malignant cell concern.
  • Pause around pregnancy: Use stops from the time of conception planning through the end of breastfeeding. Avoids unstudied fetal and infant exposure.

Therapeutic Protocol

  • Standard home protocol: A 2–10% NMN serum or cream applied twice daily (morning and evening) to cleansed facial skin, as in the Seneque 2% cream trial and the DEFY NUMBER 10% ampoule study, followed by moisturizer and daytime sunscreen.
  • Device-assisted clinic protocol: Korean clinics (Class One, Benjamin) working with device maker Hironic pair cold plasma (ionized gas) pretreatment with weekly electroporation-microjet delivery of 10% nano-NMN for 4 weeks (Hong et al., 2026); reported changes were larger but unblinded.
  • Oral NMN approach: Longevity practitioners, following David Sinclair’s public advocacy, use 250–1,200 mg/day orally; this targets whole-body NAD+ rather than skin, and no oral trial has measured skin endpoints.
  • Established topical comparator: Niacinamide 5% twice daily improved wrinkles, pigment and elasticity versus vehicle in a Procter & Gamble-funded trial (Bissett et al., 2005); many NMN products already include it.
  • Time of day: NAD+ production follows the body clock and skin repair peaks overnight, a rationale for evening use, but no study has tested timing; twice-daily application is the only tested schedule.
  • Half-life: Oral NMN leaves mouse blood within minutes (Mills et al., 2016); skin residence time is unmeasured, and NMN in a water-based ferment had a shelf half-life of about 7 months at 20°C (Betsuno et al., 2025).
  • Single versus split application: Both human studies used twice-daily split application; no once-daily comparison exists.
  • Genetic polymorphisms: No genotype-guided dosing exists; NAMPT, NNMT and CD38 variants have not been studied for topical response.
  • Sex: No sex-specific dosing exists; human topical data are from women only.
  • Age: Studied in women aged 40–73; older skin with lower NAD+ may respond more in theory, while thinner skin favours starting at lower concentrations.
  • Baseline biomarkers: Lower baseline hydration, deeper wrinkles or heavier pigment leave more room for measurable change, and aged skin with lower NAD+ may respond more; baseline instrument readings define the reference, and no blood test guides dosing.
  • Pre-existing conditions: Rosacea, eczema or sensitive skin favour lower concentrations and patch testing; a history of skin cancer favours dermatologist oversight.

Discontinuation & Cycling

  • Duration: Used as ongoing cosmetic maintenance; no study has run beyond 8 weeks, so long-term use is unstudied.
  • Withdrawal effects: None expected or reported; any cosmetic gains would likely fade gradually over weeks as skin turns over.
  • Tapering: Not required; use can stop abruptly.
  • Cycling: No evidence supports cycling to maintain efficacy, and no tolerance mechanism is known.

Sourcing and Quality

  • Form and purity: β-NMN (the biologically active isomer) at ≥99% purity by HPLC (high-performance liquid chromatography, a laboratory purity test) on a batch certificate of analysis; “NMN complex” or “yeast ferment” labels may contain little NMN.
  • Stability and packaging: NMN breaks down in water; anhydrous, powder-to-serum or freshly mixed formats, opaque airless packaging and refrigeration slow this. In a yeast-fermented filtrate, NMN’s half-life was about 7 months at 20°C (Betsuno et al., 2025).
  • Concentration disclosure: Clinically tested products used 2% (Seneque) and 10% (DEFY NUMBER); products listing NMN after preservatives in the ingredient order likely contain under 1%.
  • Third-party testing: Tests commissioned by ChromaDex, a competing nicotinamide riboside maker, and reported by NutraIngredients found 13 of 14 oral NMN products labelled 500 mg held under 1% of claim or none; no equivalent program covers topicals.
  • Reputable brands: Brands with clinically tested topical formulations include Seneque (Switzerland) and DEFY NUMBER (South Korea); established NMN ingredient suppliers include Effepharm and GeneHarbor.
  • Single-active versus blends: Many serums combine NMN with niacinamide, peptides or hyaluronic acid, making effects hard to attribute; single-active formulations isolate NMN’s contribution.

Practical Considerations

  • Time to effect: Instrumental changes appeared at 4 weeks in the one published study; the Seneque trial assessed 28 and 56 days. Collagen-related change with established actives typically takes 8–12 weeks.
  • Common pitfalls: Buying degraded or underdosed products; expecting whole-body effects from topical use; replacing proven measures such as daily sunscreen and retinoids; attributing results from multi-ingredient serums to NMN alone.
  • Regulatory status: Sold as a cosmetic ingredient (INCI, International Nomenclature of Cosmetic Ingredients, name “Nicotinamide Mononucleotide”); not an approved drug and not permitted disease claims. The US Food and Drug Administration confirmed oral NMN lawful in supplements in September 2025.
  • Cost and accessibility: NMN serums generally cost more than niacinamide equivalents, and device-assisted clinic sessions add procedural fees. Neither NMN nor its topical alternatives are reimbursed by insurers or health systems, so payers have no financial stake shaping this evidence.
  • Evidence provenance: Nearly all topical data come from product makers (Seneque, DEFY NUMBER, LG Household & Health Care) or a device maker (Hironic).

Interaction with Foundational Habits

  • Sleep: No direct interaction (none known). NAD+ production follows the body clock and skin repair peaks overnight, offering an untested rationale for evening application. Topical NMN has no reported effect on sleep.
  • Nutrition: Indirect interaction. Dietary vitamin B3 (meat, fish, legumes) and tryptophan feed the same NAD+ pathway; adequate protein and vitamin C support collagen synthesis. High sugar intake promotes glycation (sugar cross-linking of collagen), which NMN has not been shown to reverse.
  • Exercise: Indirect interaction. Exercise training raises NAMPT expression in human muscle (Sun et al., 2023), a separate NAD+ route. Heavy sweating after application may dilute or remove product, so application after post-workout cleansing is practical; outdoor training adds ultraviolet exposure.
  • Stress management: No direct interaction reported. Psychological stress and cortisol impair skin barrier recovery; NMN has not been shown to blunt this, so stress reduction and sleep likely matter more for barrier function than any topical precursor.

Monitoring Protocol & Defining Success

Baseline assessment before starting consists of standardized facial photographs (same camera, lighting, distance and time of day) and, where available, clinic-based instrumental readings of wrinkle depth, hydration, TEWL, elasticity and melanin. A full-skin examination documents existing spots so that any new or changing lesion is recognized. No blood tests are required for topical use, and no functional-medicine optimal ranges exist for these skin measures.

Ongoing monitoring repeats the photographs and instrumental readings at 4 weeks, 12 weeks, then every 3–6 months while the product is used; the full-skin examination is repeated yearly, or every 6 months with a history of skin cancer. Irritation persisting beyond 1 week, or any new or changing lesion, prompts stopping and reassessment. Success is a consistent improvement from the individual’s own baseline.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Standardized facial photography No established target; track change from own baseline Documents visible wrinkles, tone and texture Same camera, lighting, angle and time of day; no fasting needed; best paired with 3D imaging
Wrinkle depth (3D skin imaging) No established target; track % reduction from own baseline Objective wrinkle and pore measure Crow’s feet and nasolabial folds; clinic devices such as Antera 3D; no conventional reference range exists
Skin hydration (corneometer) No universal target (device-specific units); track rise from own baseline Surface water content Acclimatize 15–20 minutes at 20–22°C, 40–60% humidity; morning readings; pair with TEWL
TEWL (tewameter) No established target; lower than or equal to own baseline Barrier function and early irritation signal TEWL = transepidermal water loss; same acclimatization as hydration; rises with irritation or over-exfoliation
Skin elasticity (cutometer R2) No established target; higher than own baseline Firmness and elastic recovery R2 = gross elasticity score; same site and time of day; values fall with age; no conventional reference range
Melanin index (colorimeter or imaging) No established target; lower in treated spots than own baseline Tracks pigment and tone evenness Seasonal sun exposure confounds readings; compare same season and site
Full-skin examination No new or changing lesions Screens for pre-malignant or malignant change Dermatologist-performed; yearly, or every 6 months with prior skin cancer

Qualitative markers:

  • Perceived smoothness and fine-line visibility
  • Tone evenness and radiance in daylight
  • Tightness, dryness or flaking after cleansing
  • Stinging, redness or itching after application
  • Makeup application and skin texture

Emerging Research

  • Unpublished topical NMN trial: “Anti-ageing Efficacy of a Cosmetic Formulation Containing NMN (2%) Versus Placebo” (NCT04685096); Seneque-sponsored, 89 women aged 40–65 with Asian or African-American skin; wrinkles, eye bags and dark circles at 28 and 56 days. Completed in 2021 with no results posted; publication could strengthen or weaken the case.
  • Topical nicotinamide riboside dose-response trial: NCT07774000; ChromaDex-sponsored, 140 women aged 30–60, randomized, placebo versus 2.5%, 5% and 10% for 12 weeks; primary endpoints skin biological age, eye wrinkles and firmness. Results for this sister precursor will test the topical NAD+-precursor rationale.
  • Oral multi-ingredient product containing NMN: NCT07703215; NPQ Plus (NMN, pyrroloquinoline quinone, coenzyme Q10, polyphenols), 55 adults, single-arm, 12 weeks; primary endpoints elasticity, hydration and water loss. Completed in 2026, results not posted; uncontrolled and multi-ingredient.
  • Delivery technology: Elastic cationic liposomes and liposomal nanogels (gel particles carrying these liposomes) raised NMN skin penetration by 22.7% and 16.0% over free NMN (Ye et al., 2026), and NMN-loaded stem-cell vesicles slowed skin aging in mice (Sun et al., 2025).
  • Precursor choice in surface skin cells: Nicotinic acid raised keratinocyte NAD+ 1.3-fold whereas nicotinamide derivatives did not (Oyama et al., 2024, cosmetics-maker authors); if replicated, NMN may be a weaker epidermal precursor, which would weaken the case.
  • Skin cancer claims: Oral NMN raised skin NAD+ but did not protect mice from ultraviolet-induced tumors (Pihl et al., 2025), unlike oral nicotinamide, which cut new non-melanoma skin cancers by 23% in a phase 3 trial (Chen et al., 2015).
  • Proof of skin delivery: Transdermal NMN suppressed inflammation in mice lacking epidermal NAMPT (Seki et al., 2026), showing topically applied NMN can reach and act in living epidermis, which strengthens the delivery case.
  • Keratinocyte inflammation: NMN reduced inflammatory cytokine (signaling protein) production more broadly than nicotinamide riboside in stimulated human keratinocytes (Xie et al., 2026).

Conclusion

Topical NMN is a vitamin B3 building block applied to the skin in the hope of restoring a molecule that cells need for energy and DNA repair, whose levels fall in aging skin. The idea is biologically coherent: in cell and animal studies it supports collagen, calms inflammation, lowers pigment production in older pigment cells and protects against sun damage.

In people, the picture is much thinner. The only published human data on topical NMN alone show small improvements in wrinkles, firmness, tone and hydration over one month, without a comparison product and with other active ingredients in the formula. A larger cream study finished years ago, but its results have not been released. Nearly all of this evidence comes from companies that sell NMN products or delivery devices, and the reassuring safety data on its breakdown product come from a panel funded by the cosmetics industry, which limits confidence. Whether NMN even raises the target molecule in surface skin cells is disputed.

Safety looks reassuring so far: no irritation has been reported, and NMN taken orally at far larger amounts has been well tolerated. The main practical hazards come from how it is applied, such as needling devices pushing ordinary serums under the skin, rather than from the molecule itself. Concerns about feeding damaged or pre-cancerous cells remain theoretical.

For people already running a thorough skincare routine, topical NMN is a plausible but largely unproven addition whose benefits, if real, appear modest and whose main cost is financial.

Top - Benefits - Risks - Protocol